FDA To Regulate Direct-To-Consumer Genetic Tests
This article was originally published in The Tan Sheet
Executive Summary
FDA sent letters to five genetic testing firms requesting pre-market submissions for the companies' already-marketed services, citing the need to prove that direct-to-consumer genetic assays are analytically and clinically accurate
You may also be interested in...
GAO Finds "Personalized" Supplement Offers In DTC Genetic Testing Report
An investigation into direct-to-consumer genetic testing products finds some firms marketing allegedly customized dietary supplement regimens to consumers based on their test results
NIH's Collins Supports "More Aggressive" DTC Genetic Testing Oversight
National Institutes of Health Director Francis Collins, an influential supporter of genomic research and applications, says he has been urging FDA to take a "more aggressive role" in overseeing direct-to-consumer genetic tests
FDA Cites Long-Term Precedent In Blocking Retail Genetic Screening Plans
A particularly public pre-emptive stance by FDA's in vitro diagnostics oversight office halts Pathway Genomics' plans to start selling genetic screening test sample collection kits out of Walgreens stores, but the office's director stresses the move does not signal any changes to its enforcement policy for laboratory-developed tests